Spruce BiosciencesSPRB
Recorded

Spruce Biosciences 3rd Annual Guggenheim Healthcare Innovation Conference

Review the key takeaways and the transcript of this earnings call.

PeriodFY 0Duration21 minParticipants2

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Debjit ChattopadhyayBiotechnology

All right. Good morning, and thank you for joining Guggenheim's 3rd Annual Healthcare Innovation Conference. I'm Debjit, and my privilege to welcome Javier Szwarcberg. Did I get that right?

Debjit ChattopadhyayBiotechnology

Perfectly pronounced. CEO of Spruce Biosciences.

Debjit ChattopadhyayBiotechnology

Thank you for making time for us, Javier. I don't think people still appreciate the story as much, so maybe just give us a very quick intro, then we can dive into the TA-ERT program for MPS.

Javier SzwarcbergCEO

Yeah. We're an ultra-rare disease company focused on pediatric neurology. Our lead asset is tralesinidase alfa, which is an enzyme replacement therapy that is very unique in its construct. It's a fusion protein that is tagged with a truncated IGF-2 that allows for neuronal and lysosomal penetration. The drug is delivered straight into the CSF through a port and an Ommaya reservoir, weekly or every other week. The effect sizes that we've seen in the context of patients with MPS IIIB on the approval endpoint, heparan sulfate, are incredibly profound, and we also have super strong clinical data on efficacy and safety that supports the product. There's no other product being approved for this indication.

Javier SzwarcbergCEO

The field is really clamoring a life-transforming therapy like ours, and we think that the package that we have put together, which we plan to submit to the FDA in December for BLA review, meets the regulatory standards for a proper package. We have had a number of interactions with the FDA, including two pre-BLA meetings, one on CMC and one on clinical, whereby we ask 10 questions on CMC and 10 on clinical to allow us to really discuss with the FDA what to include, the framework, the structure of the BLA. All in all, from our point of view, a very tight story. We have been partnering with our key stakeholders, like patient groups, engaging with caregivers on educational efforts, obviously with the overall community, and it has been a very nourishing experience and a very strong partnership.

Debjit ChattopadhyayBiotechnology

Got it. With your quarterly update, which just came out, the most important update from our side was the second PPQ run, which should be completed by the end of the year. Is that getting rolled into the BLA, or that is going to get submitted after you submit the BLA?

Javier SzwarcbergCEO

We aligned with the FDA to include the first PPQ batch, both drug substance and drug product, with the BLA. The second PPQ will get included and submitted during review. FDA wanted to see the analytical report for the DS and the DP included prior, submitted to the BLA prior to the mid-cycle meeting, and we are well on track to do that. We already completed the drug substance piece of that PPQ, although the drug substance PPQ batches have already been qualified, and we have over four years of shelf life on the DS. It is the DP that changed manufacturing sites from Vetter in Germany to Samsung Biologics in South Korea, which need to be qualified.

Debjit ChattopadhyayBiotechnology

Got it. You touched upon the biomarker data, which are very, very compelling, and there is a precedent in the market for approval with the same biomarker.

Debjit ChattopadhyayBiotechnology

Do you think that completely de-risks any FDA or regulatory headwinds there?

Javier SzwarcbergCEO

Well, I wouldn't say completely de-risks, but it certainly creates a very clear pathway to approval, and it sets a regulatory precedence to an approval. Each disease, the FDA defined, when they looked at our biomarker data, they told us that we have an endpoint that is reasonably likely to predict clinical benefit. Obviously, the acceptance of the biomarker as an RLSE becomes a review issue. I think that the body of evidence in the context of heparan sulfate, the body of evidence that supports heparan sulfate non-reducing ends, which is the biomarker that we're using as a primary endpoint for the approval, the AA approval, the data is incredibly robust. We've also done, since we've acquired the asset, a whole body of work to look at endpoints, clinical endpoints that relate to cognition as well as adaptive behavior through different questionnaires.

Javier SzwarcbergCEO

We've looked at structural imaging using cortical gray matter volume, looking at peripheral efficacy, looking at MRI liver and spleen size. Lately, I've measured a number of biomarkers which we haven't yet made public. We'll be sharing them to the WORLDSymposium during the WORLDSymposium meeting in February in San Diego. We'll be discussing the impact that we've had on NfL and GM2 and GM3 and other biomarkers at that time. But the whole clinical package is incredibly compelling. So, we are proceeding. Our approval is based on the AA approval pathway, and obviously, the FDA, just like it happened for FAYUVI, the drug that was recently approved by the FDA for MPS IIIA, the gene therapy product from Ultragenyx. They received a full approval for it. So, we're putting all of our cards on the table and letting the FDA decide.

Debjit ChattopadhyayBiotechnology

Yeah, and you also have aligned with the FDA on what a potential registration study is going to look like. So there are no secrets there.

Javier SzwarcbergCEO

Yeah, I mean, we've aligned with the FDA on the fact that the confirmatory trial needed to be underway at the time of the BLA submission, which was a very important piece and a big win on our end, at least from a point of view of not needing the trial to be fully recruited by the time of launch. We provided to the FDA a very clear plan to operationalize that study and what countries we would go to and how do we get it done to ensure the FDA that we can make it happen. We have initiated that trial, along with the expanded access program, which kind of covered different patient groups, and both serving different purposes.

Javier SzwarcbergCEO

The expanded access primarily to allow patients to access the product between now and hopefully commercial availability, and the confirmatory trial to ensure full approval should our approval be under the AA pathway.

Debjit ChattopadhyayBiotechnology

Do you think the FDA is going to debate any of the functional measures that you've sort of highlighted, especially comparisons with longitudinal studies where there's some potential imbalance between the ages of patients?

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.

View the full transcript with Pro

Other earnings calls that day

View calls from this day